Anaplan transformed gross‑to‑net planning for pharma and life sciences by bringing strategy, data, and decisions together on a single platform. The software connected deal evaluation, demand forecasting, WAC price changes, channel and government pricing forecasts, and revenue accruals, enabling more accurate and agile GTN predictions. By automating manual processes and capturing complex discounting nuances across portfolios and channels, Anaplan improved visibility into pricing impacts, strengthened accrual accuracy, reduced reserve distortions, and increased forecast confidence. This allowed life science companies to protect revenue, optimise pricing decisions, and drive more predictable, profitable growth across their product portfolios.

Join for free to read